Disparities in Fibroid Incidence, Prognosis, and Management

Shannon K Laughlin-Tommaso; Vanessa L Jacoby; Evan R Myers

doi:10.1016/j.ogc.2016.11.007

Disparities in Fibroid Incidence, Prognosis, and Management

Obstet Gynecol Clin North Am. 2017 Mar;44(1):81-94. doi: 10.1016/j.ogc.2016.11.007.

Authors

Shannon K Laughlin-Tommaso¹, Vanessa L Jacoby², Evan R Myers³

Affiliations

¹ Department of Obstetrics & Gynecology and Surgery, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA; Department of Surgery, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: Laughlintommaso.shannon@mayo.edu.
² Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, 2356 Sutter Street, San Francisco, CA 94115, USA.
³ Department of Obstetrics & Gynecology, Duke Clinical Research Institute, Duke University, 2400 Pratt Street, Durham, NC 27705, USA.

PMID: 28160895
DOI: 10.1016/j.ogc.2016.11.007

Abstract

Health disparities in fibroid prevalence, prognosis, and treatment exist for underserved women. Access to fibroid treatment alternatives can have significant effect on choices and outcomes of fibroid disease.

Keywords: Disparity; Fibroid; Leiomyoma; Race; Rural; Socioeconomic status.

Publication types

Review

MeSH terms

Black or African American*
Female
Health Services Accessibility / organization & administration
Health Services Accessibility / statistics & numerical data*
Healthcare Disparities / statistics & numerical data*
Humans
Hysterectomy / statistics & numerical data*
Incidence
Leiomyoma / epidemiology*
Leiomyoma / ethnology
Leiomyoma / therapy
Prognosis
Rural Population
Severity of Illness Index
United States / epidemiology
Uterine Neoplasms / epidemiology*
Uterine Neoplasms / ethnology
Uterine Neoplasms / therapy
White People*